Raymond James Financial
CLYM

Raymond James Financial’s Climb Bio CLYM Stock Holding History

Raymond James Financial’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$121K Buy
+17,727
New +$102K ﹤0.01% 4997
2025
Q3 		– Sell
-200
Closed -$248 – 6939
2025
Q2 		$248 Buy
+200
New +$249 ﹤0.01% 6757

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Raymond James Financial's CLYM Position: Q1 2026 in Review

Raymond James Financial opened a new position in Climb Bio (CLYM) in Q1 2026: 17,727 shares worth $121K. The stake represents ﹤0.01% of the portfolio and ranks #4997 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in CLYM as recently as Q2 2025.

Raymond James Financial first reported a position in CLYM in Q2 2025 and has held it in 2 quarters since. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Raymond James Financial held 17,727 shares of Climb Bio worth $121K as of Q1 2026.
  • Climb Bio was a new Raymond James Financial position in Q1 2026.
  • Climb Bio made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4997 holding.
  • Raymond James Financial first reported a position in Climb Bio in Q2 2025 and has held it in 2 quarters since.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.